Lecanemab 사용 6개월 이내 임상양상 증례보고
Case Report on Clinical Features Within Six Months of Lecanemab Use
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lecanemab is a humanized monoclonal antibody that binds with high affinity to soluble amyloid-beta protofibrils and was approved by the FDA on July 6, 2023. This case report describes the clinical setting for lecanemab administration, as well as the clinical course and adverse events following six months of treatment in four patients with Alzheimer’s disease dementia. These findings may serve as foundational information for future clinical practice and research involving monoclonal antibody therapies for Alzheimer’s disease.
Abstract
Lecanemab is a humanized monoclonal antibody that binds with high affinity to soluble amyloid-beta protofibrils and was approved by the FDA on July 6, 2023. This case report describes the clinical setting for lecanemab administration, as well as the clinical course and adverse events following six months of treatment in four patients with Alzheimer’s disease dementia. These findings may serve as foundational information for future clinical practice and research involving monoclonal antibody therapies for Alzheimer’s disease.